Abstract
HIV-1 can persist in a latent form in resting memory CD4+ cells and macrophages carry an integrated copy of the HIV genome. Because of the presence of these stable reservoir cells, eradication by antiretroviral therapy is unlikely, and in order to achieve eradication, alternative treatment options are required. Recently, we have described a successful hematopoietic stem cell transplantation in an HIV-1 infected patient by transferring donor derived cells with a natural resistance against HIV infection (CCR5-delta 32 deletion). At present the patient is more than 6 years after allogeneic transplantation without requirement of any antiretroviral treatment. Here we report the potential and limitations concerning this stem cell based approach.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T (2011) Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117:2791–2799
Avettand-Fenoel V, Mahlaoui N, Chaix ML, Milliancourt C, Burgard M, Cavazzana-Calvo M, Rouzioux C, Blanche S (2007) Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART. AIDS 21:776–777
Bogunia-Kubik K, Duda D, Suchnicki K, Lange A (2006) CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 91:1628–1634
Burke BP, Boyd MP, Impey H, Breton LR, Bartlett JS, Symonds GP, Hütter G (2013) CCR5 as a natural and modulated target for inhibition of HIV. Viruses 6:54–68
Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667–673
Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, Panzer U, Stahl RA, Hauser IA, Budde K, Neumayer H, Kramer BK, Land W, Schlondorff D (2001) CC chemokine receptor 5 and renal-transplant survival. Lancet 357:1758–1761
Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203:35–40
Hassett JM, Zaroulis CG, Greenberg ML, Siegal FP (1983) Bone marrow transplantation in AIDS. N Engl J Med 309:665
Hayat MA (ed) (2012–2014) Stem cells and cancer stem cells. Therapeutic applications in disease and injury, vol 1–12. Springer, Heidelberg/New York
Heidenhain C, Puhl G, Moench C, Lautem A, Neuhaus P (2009) Chemokine receptor 5Delta32 mutation reduces the risk of acute rejection in liver transplantation. Ann Transpl 14:36–44
Henrich T, Hanhauser E, Sirignano M, Davis B, Lee TH, Keating S, Busch M, Marty F, LaCasce A, Armand P, Soiffer R, Altfeld M, Kuritzkes D (2013a) In depth investigation of peripheral and gut HIV-1 reservoirs, HIV-specific cellular immunity, and host microchimerism following allogeneic hematopoetic stem cell transplantation. In: 7th international AIDS society conference on HIV pathogenesis, treatment and prevention, Kuala Lumpur, p. WELBA05
Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DR (2013b) Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 207:1694–1702
Hütter G, Zaia JA (2011) Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol 163:284–295
Hütter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360:692–698
Kamp C, Wolf T, Bravo IG, Kraus B, Krause B, Neumann B, Winskowsky G, Thielen A, Werner A, Schnierle BS (2010) Decreased HIV diversity after allogeneic stem cell transplantation of an HIV-1 infected patient: a case report. Virol J 7:55
Kwon M, Balsalobre P, Serrano D, Perez CA, Buno I, Anguita J, Gayoso J, Diez-Martin JL (2012) Single cord blood combined with HLA-mismatched third party donor cells: comparable results to matched unrelated donor transplantation in high-risk patients with hematologic disorders. Biol Blood Marrow Transpl 19:143–149
Lazar K (2013) HIV virus returns after cure hope rose. In: Boston Globe, 6 Dec 2013 https://www.bostonglobe.com/lifestyle/health-wellness/2013/12/05/hiv-virus-returns-after-curehope-rose/kSUyH1YkgJ27AP4aZwpUXJ/story.html
Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Tonai R, Santos S, Bravo A, Spellman S, Gragert L, Rossi J, Li S, Li H, Senitzer D, Zaia J, Rosenthal J, Forman S, Chow R (2012) Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transpl 19:393–397
Polizzotto MN, Shortt J, Cole-Sinclair MF, Opat SS, Spencer A, Avery S (2007) Allogeneic peripheral blood stem cell transplantation for hematological malignancies in patients with HIV. ASH Annu Meet Abstr 110:4941
Schnickel GT, Bastani S, Hsieh GR, Shefizadeh A, Bhatia R, Fishbein MC, Belperio J, Ardehali A (2008) Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J Immunol 180:4714–4721
Siliciano JD, Siliciano RF (2004) A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 54:6–9
Sora F, Antinori A, Piccirillo N, De Luca A, Chiusolo P, Cingolani A, Laurenti L, Rutella S, Ortona L, Leone G, Sica S (2002) Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia. Exp Hematol 30:279–284
Symons J, Deeks S, Hütter G, Wensing A, van Ham P, Vandekerckhove L, Nijhuis M (2012) CCR5-dependence prevents X4-tropic HIV-rebound post CCR5-delta32-SCT in the ‘Berlin. JIAS 15:16–17
Tomich CH, da Silva P, Carvalho I, Taft CA (2005) Homology modeling and molecular interaction field studies of alpha-glucosidases as a guide to structure-based design of novel proposed anti-HIV inhibitors. J Comput Aided Mol Des 19:83–92
Wolf T, Rickerts V, Staszewski S, Kriener S, Wassmann B, Bug G, Bickel M, Gute P, Brodt HR, Martin H (2007) First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemia. Haematologica 92:e56–e58
Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, Deeks SG (2013) Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 9, e1003347
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Hütter, G. (2015). Transplantation of CCR5-Δ32/Δ32 Stem Cells May Cure HIV Infection. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells, Volume 13. Stem Cells and Cancer Stem Cells, vol 13. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7233-4_3
Download citation
DOI: https://doi.org/10.1007/978-94-017-7233-4_3
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7232-7
Online ISBN: 978-94-017-7233-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)